While Amgen's (NASDAQ: AMGN) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
1don MSN
The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...
A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgen’s market cap. The tab ...
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...
Shares of Amazon.com Inc. and Amgen are retreating Friday afternoon, sending the Dow Jones Industrial Average into negative territory.
Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, ...
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Amgen (NasdaqGS:AMGN) with a Peer Perform ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback